LSD Therapy for Persons Suffering From Major Depression
Randomised, double-blind, active-placebo-controlled Phase II trial (n=60) of two-session LSD-assisted psychotherapy (100 µg → 100/200 µg) versus low-dose LSD (25 µg ×2) for Major Depressive Disorder.
Details
This randomised, double-blind, parallel-group trial tests LSD-assisted psychotherapy in patients with Major Depressive Disorder using two dosing sessions and an active low-dose comparator.
Sixty participants aged over 25 will receive psychotherapy with either moderate/high-dose LSD (100 µg then 100 or 200 µg) or low-dose LSD (25 µg in both sessions); outcomes include depressive symptoms (IDS, BDI), anxiety (STAI) and general psychopathology (SCL-90).
Masking is quadruple and the trial is registered on ClinicalTrials.gov (NCT03866252); primary purpose is treatment.